Debt-to-Equity Ratio

With a debt-to-equity ratio of -3.25x, bluebird bio has more total liabilities than total assets, meaning its shareholder equity is negative — this metric measures how much debt a company uses to finance its operations relative to its own equity.

This ratio places the company at the 2nd percentile among Healthcare sector peers, far below the sector median of 0.45x, indicating a much higher reliance on debt relative to equity than most competitors. The year-over-year and quarter-over-quarter changes are not available (N/A), so no trend can be assessed from the provided data. The combination of an extremely negative ratio and no trend information suggests elevated financial risk, as negative equity typically signals past losses exceeding invested capital and potential difficulty meeting debt obligations. This metric contradicts the overall NEUTRAL verdict because a debt-to-equity ratio deeply below zero is an acute red flag that often warrants a more cautious stance.

Frequently Asked Questions

Closest Sector Peers